S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

Pacira BioSciences (PCRX) Competitors

$26.25
+0.15 (+0.57%)
(As of 04/19/2024 08:51 PM ET)

PCRX vs. SUPN, OPK, ALXO, ADCT, AVIR, NKTR, MCRB, CORT, ALKS, and PRGO

Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Supernus Pharmaceuticals (SUPN), OPKO Health (OPK), ALX Oncology (ALXO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), Nektar Therapeutics (NKTR), Seres Therapeutics (MCRB), Corcept Therapeutics (CORT), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.

Pacira BioSciences vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
471
73.25%
Underperform Votes
172
26.75%
Pacira BioSciencesOutperform Votes
807
71.73%
Underperform Votes
318
28.27%

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$607.52M2.65$1.32MN/AN/A
Pacira BioSciences$674.98M1.81$41.96M$0.8132.41

99.7% of Pacira BioSciences shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pacira BioSciences has a net margin of 6.22% compared to Pacira BioSciences' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 12.81% beat Pacira BioSciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals0.22% 0.14% 0.09%
Pacira BioSciences 6.22%12.81%6.80%

Supernus Pharmaceuticals has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

In the previous week, Supernus Pharmaceuticals had 1 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Supernus Pharmaceuticals and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.51 beat Supernus Pharmaceuticals' score of 0.37 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacira BioSciences
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Supernus Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 39.46%. Pacira BioSciences has a consensus price target of $49.50, suggesting a potential upside of 88.57%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pacira BioSciences
0 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Pacira BioSciences beats Supernus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Pacira BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCRX vs. The Competition

MetricPacira BioSciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.22B$6.42B$4.88B$7.32B
Dividend YieldN/A3.10%2.92%3.97%
P/E Ratio32.4110.56185.3917.46
Price / Sales1.81307.642,464.7281.89
Price / Cash6.6328.9747.5134.38
Price / Book1.405.324.574.15
Net Income$41.96M$140.57M$104.42M$214.00M
7 Day Performance-2.16%-6.71%-4.52%-3.51%
1 Month Performance-10.38%-9.68%-6.82%-6.05%
1 Year Performance-44.74%-6.66%6.59%3.98%

Pacira BioSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
3.874 of 5 stars
$29.43
-1.9%
$41.00
+39.3%
-24.1%$1.61B$607.52M0.00652News Coverage
OPK
OPKO Health
4.74 of 5 stars
$1.21
-1.6%
$3.73
+207.9%
-18.8%$843.36M$863.50M-4.843,930Analyst Revision
ALXO
ALX Oncology
1.4685 of 5 stars
$14.49
+12.4%
$18.83
+30.0%
+160.0%$726.67MN/A-3.8672High Trading Volume
ADCT
ADC Therapeutics
2.0012 of 5 stars
$4.42
+1.1%
$7.50
+69.7%
+105.2%$364.78M$69.56M-1.51273Short Interest ↑
Analyst Revision
News Coverage
AVIR
Atea Pharmaceuticals
0.4901 of 5 stars
$3.74
-0.5%
N/A+13.4%$314.80M$351.37M-2.2875Positive News
NKTR
Nektar Therapeutics
4.0056 of 5 stars
$1.49
-5.1%
$3.50
+134.9%
+42.5%$273.59M$90.12M-1.02137News Coverage
MCRB
Seres Therapeutics
3.6438 of 5 stars
$0.64
+3.2%
$6.67
+948.1%
-91.3%$96.06M$126.32M-0.71233
CORT
Corcept Therapeutics
4.7144 of 5 stars
$23.39
+1.0%
$37.30
+59.5%
+2.2%$2.42B$482.38M24.62352Analyst Downgrade
Short Interest ↑
Analyst Revision
News Coverage
ALKS
Alkermes
4.6763 of 5 stars
$23.77
-1.0%
$35.25
+48.3%
-18.8%$4.02B$1.66B11.482,100Analyst Report
PRGO
Perrigo
4.928 of 5 stars
$29.96
-0.6%
$40.67
+35.7%
-15.5%$4.06B$4.66B-299.609,140

Related Companies and Tools

This page (NASDAQ:PCRX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners